文献速递神经介入DSA

新型成像平台在神经诊断与介入X线血管造影中降低患者辐射暴露

Reduced Patient Radiation Exposure during Neurodiagnostic and Interventional X-Ray Angiography with a New Imaging Platform.
PubMed 文献 · AJNR Am J Neuroradiol · 2017-01-19

单中心回顾性研究纳入1238例神经介入手术,比较减剂量平台(324例)与参考平台(914例)的累积剂量面积乘积、透视时间和对比剂用量。减剂量平台使累积剂量面积乘积显著降低53.2%(平均减少160.3 Gy×cm²,P<.0001),透视时间轻度显著增加(平均增加5.2分钟,P=.0491),对比剂用量非显著增加(平均增加15.3 mL,P=.1616)。

要点

  • 减剂量平台使神经血管手术累积剂量面积乘积显著降低53.2%(平均减少160.3 Gy×cm²,P<.0001)。
  • 透视时间轻度显著增加(平均增加5.2分钟,P=.0491),对比剂用量非显著增加(平均增加15.3 mL,P=.1616)。
  • 减剂量技术对工作流程影响最小,可在神经血管手术中显著降低患者辐射剂量。

核心结论

  • 使用结合图像降噪、运动校正和对比剂依赖时间平均及优化X线曝光设置的减剂量技术平台,可在神经血管手术中显著降低患者辐射剂量,且对工作流程影响最小。

研究设计与样本

  • 单中心回顾性研究,纳入2年期间所有神经血管手术共1238例,其中参考平台914例、减剂量平台324例;比较累积剂量面积乘积(含透视、血管造影和3D采集)、透视时间和对比剂用量,统计分析纳入患者特征和神经介入放射科医生作为协变量。

临床应用与阅片要点

  • 神经介入放射科医生可在减剂量平台上为每位患者选择目标减剂量水平;阅片和报告时可关注该平台在降低累积剂量面积乘积(平均减少160.3 Gy×cm²,P<.0001)的同时透视时间轻度增加(平均增加5.2分钟,P=.0491)。

局限性

  • 本研究为单中心回顾性研究。
  • 减剂量平台上神经介入放射科医生可为每位患者选择目标减剂量水平,可能影响剂量比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Advancements in medical device and imaging technology as well as accruing clinical evidence have accelerated the growth of the endovascular treatment of cerebrovascular diseases. However, the augmented role of these procedures raises concerns about the radiation dose to patients and operators. We evaluated patient doses from an x-ray imaging platform with radiation dose-reduction technology, which combined image noise reduction, motion correction, and contrast-dependent temporal averaging with optimized x-ray exposure settings.

MATERIALS AND METHODS: In this single-center, retrospective study, cumulative dose-area product inclusive of fluoroscopy, angiography, and 3D acquisitions for all neurovascular procedures performed during a 2-year period on the dose-reduction platform were compared with a reference platform. Key study features were the following: The neurointerventional radiologist could select the targeted dose reduction for each patient with the dose-reduction platform, and the statistical analyses included patient characteristics and the neurointerventional radiologist as covariates. The analyzed outcome measures were cumulative dose (kerma)-area product, fluoroscopy duration, and administered contrast volume.

RESULTS: A total of 1238 neurointerventional cases were included, of which 914 and 324 were performed on the reference and dose-reduction platforms, respectively. Over all diagnostic and neurointerventional procedures, the cumulative dose-area product was significantly reduced by 53.2% (mean reduction, 160.3 Gy × cm2; P < .0001), fluoroscopy duration was marginally significantly increased (mean increase, 5.2 minutes; P = .0491), and contrast volume was nonsignificantly increased (mean increase, 15.3 mL; P = .1616) with the dose-reduction platform.

CONCLUSIONS: A significant reduction in patient radiation dose is achievable during neurovascular procedures by using dose-reduction technology with a minimal impact on workflow.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. van der Marel K, Vedantham S, van der Bom IM, et al. Reduced Patient Radiation Exposure during Neurodiagnostic and Interventional X-Ray Angiography with a New Imaging Platform. AJNR Am J Neuroradiol. 2017. PMID: 28104643. doi:10.3174/ajnr.A5049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。